Research Article

Assessment of the Relaxation-Enhancing Properties of a Nitroxide-Based Contrast Agent TEEPO-Glc with In Vivo Magnetic Resonance Imaging

Maiju Soikkeli,1 Mikko I. Kettunen,2 Riikka Nivajärvi,2 Venla Olsson,2 Seppo Rönkkö,3 Johanna P. Laakkonen,2 Vesa-Pekka Lehto,3 Jari Kavakka,1 and Sami Heikkinen1

1Department of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland
2A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, FI-70211 Kuopio, Finland
3Department of Applied Physics, University of Eastern Finland, FI-70211 Kuopio, Finland

Correspondence should be addressed to Sami Heikkinen; sami.heikkinen@helsinki.fi

Received 30 October 2019; Accepted 26 November 2019

Academic Editor: Guillermina Ferro-Flores

Copyright © 2019 Maiju Soikkeli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Magnetic resonance imaging examinations are frequently carried out using contrast agents to improve the image quality. Practically all clinically used contrast agents are based on paramagnetic metals and lack in selectivity and specificity. A group of stable organic radicals, nitroxides, has raised interest as new metal-free contrast agents for MRI. Their structures can easily be modified to incorporate different functionalities. In the present study, a stable nitroxide TEEPO (2,2,6,6-tetraethylpiperidin-1-oxyl) was linked to a glucose moiety (Glc) to construct a water-soluble, potentially tumor-targeting compound with contrast-enhancing ability. The ability was assessed with in vivo MRI experiments. The constructed TEEPO-Glc agent proved to shorten the $T_1$ relaxation time in tumor, while the $T_1$ time in healthy brain tissue remained the same. The results indicate the potential of TEEPO-Glc as a valuable addition to the growing field of metal-free contrast enhancement in MRI-based diagnostics.

1. Introduction

Magnetic resonance imaging (MRI) is one of the most prominent imaging modalities due to its superior versatility, soft tissue contrast, and resolution. Although optimizing imaging conditions often leads to excellent image quality, in some cases, the contrast between pathologies and healthy tissue is improved by utilizing contrast agents (CAs). Contrast agents can also increase the signal-to-noise ratio (SNR) leading to better image quality and resolution. Traditional contrast agents are mainly based on a paramagnetic gadolinium metal due to its seven unpaired electrons, high magnetic moment, and long electron spin relaxation [1, 2]. However, free Gd$^{3+}$ is toxic in human body mainly due to its identical ionic size with Ca$^{2+}$. As a result, it can potentially bind to Ca$^{2+}$ channels and disturb protein synthesis [3]. Therefore, gadolinium is tightly bound with organic ligands, increasing both its kinetic inertness and thermodynamic stability [2]. In 2006, it was reported that the use of gadolinium-based contrast agents (GBCAs) on patients with renal impairment could cause nephrogenic systemic fibrosis (NSF) [4]. Later on, the prevalence of NSF was linked with the use of less stable, linear contrast agents. With thorough patient screening and restricted use of certain GBCAs, their use has been generally considered safe. Until 2015, it was prevailed that with patients going through several scans with GBCAs, gadolinium can deposit in brain [5]. Although the retention of gadolinium has not been found to be harmful for patients, the European Medical Agency (EMA) recommended suspension or restricted the use of four linear GBCAs [6]. Another concerning aspect, due to the broad use of GBCAs, is the findings of anthropogenic gadolinium in
aquatic environments [7] and even in drinking water [8]. Therefore, the development of new, metal-free contrast agents has accelerated.

Two general approaches to avoid the use of metals in CAs are the exploitation of chemical exchange saturation transfer (CEST) [9,10] or hyperpolarized [11–13] MRI contrast agents. However, these methods are quite complex and often require special techniques or dedicated hardware, which often causes some restrictions to their clinical applicability. Lately, a group of contrast agents based on paramagnetic stable radicals, nitroxides, has emerged. The applicability of nitroxides in MRI was discovered already in the 1980s [14]. Nitroxide radicals have a wide range of applications in organic synthesis [15,16], radical polymerization [17], spin labelling [18], as molecular magnets [19], and organic batteries [20–22]. Nitroxides are often prone to reduction by various natural reductants such as ascorbic acid or enzymes, which leads to formation of their diamagnetic equivalents, hydroxylamines. However, nitroxides with bulky side groups have shown remarkable stability in conditions mimicking biological matrix [23,24]. The research of nitroxide-based contrast agents comprises both macromolecular [25–31] and small molecule [32–36] systems. It is often considered that the advantage of using polymers or nanomaterials as a backbone for nitroxides is the possibility to attach several radical centers to the contrast agent molecule. Also, large molecules often have long rotational correlation times indicating their tumbling rates, which increases the relaxation of the contrast agent [25]. However, increasing the size of the contrast agent molecule also has unfavorable effects on tissue penetration and delivery [2].

Our study has focused on attaching a highly stable nitroxide, TEEPO (2,2,6,6-tetraethylpiperidin-1-oxyl), to natural compound moieties that can potentially act as targeting units [35,36]. The method is commonly applied in the use of radiopharmaceuticals as tracers in PET (positron emission tomography) imaging [37]. In our first study, we presented the synthesis of TEEPO-Glc (Figure 1), where TEEPO is covalently attached to a glucose molecule [35]. One of the main advances of using glucose is its ability to increase the water solubility of the otherwise lipophilic TEEPO. Our study presented superior stability of the compound in a matrix mimicking biological environment and against a natural reductant ascorbic acid. It also displayed a preliminary study on its cytotoxicity and relaxation enhancement properties in in vitro NMR and phantom MRI experiments. Herein, we present the results of a more detailed in vitro cytotoxicity study and also the relaxation enhancing properties with in vivo MRI experiments.

2. Materials and Methods

2.1. In Vitro Cytotoxicity Study. The preparation of the TEEPO-Glc contrast agent as well as the cell viability study with HeLa cells is described in earlier publication [35]. For the in vitro cytotoxicity studies, HeLa cells were cultured in a complete cell culture medium composed of Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich, UK), 10% heat-inactivated fetal bovine serum (Gibco, Life Technologies/Thermo Fisher Scientific, US), penicillin (100 U/ml), and streptomycin (100 μg/ml) (Gibco, Life Technologies/Thermo Fisher Scientific, US). The cells were maintained in standard cell culture conditions (37°C, 5% CO2 and 95% humidity) in a Sanyo MCO-18AIC CO2 incubator (Sanyo Electric, Osaka, Japan). The HUVECs (human umbilical vein endothelial cells; Lonza) were grown on 0.1% gelatin-coated 100 mm cell culture dishes and passage numbers from P8 to P9 were used for the experiments. The cells were maintained in a complete medium containing M199 (Gibco, Life Technologies/Thermo Fisher Scientific, US), 15% fetal bovine serum, heparin (5 units/ml) (Sigma-Aldrich, UK), endothelial cell growth factor (20 μg/ml) (ECGF, Roche Biomolecules, Switzerland), 1% L-glutamine, 1% streptomycin, and 1% penicillin, in a 5% CO2 incubator at 37°C.

To study the cell viability with HUVECs, the cells (10,000 cells per well) were seeded on 0.1% gelatin-coated 96-well tissue culture plates, and they were allowed to attach for 24 h. After two washes with phosphate-buffered saline (PBS) (200 μl per well), the cells were treated with TEEPO-Glc (0.2, 1, and 10 mM in culture medium) for 1, 6, and 24 h. The cell viability was measured using the CellTiter-Glo® reagent (Promega, US) with a Fluoroskan Ascent FL (Thermo Labsystems, US) luminometer according to the manufacturer’s instructions. For the LDH release assay, HeLa cells (10,000 cells per well) were seeded on 96-well tissue culture plates (Corning Inc., Corning, NY, US) and HUVECs (10,000 cells per well) on 0.1% gelatin-coated 96-well tissue culture plates. They were allowed to attach for 24 h. After two washes with PBS (200 μl per well), cells were treated with TEEPO-Glc (0.2, 1, and 10 mM in culture medium) for 1, 6, and 24 h. After exposure, the release of LDH was monitored from an aliquot of 50 μl of the supernatant using a Fluoroskan Ascent FL (Thermo Labsystems, US) luminometer according to the manufacturer’s instructions. The absorbance was determined with a Bio-Rad microplate reader (model-550) (Bio-Rad, US) at a wavelength of 490 nm. The release of LDH in untreated cells was used as a control. The cells lysed with the lysis solution provided in the LDH assay kit were used as a positive control and set at 100% LDH release. Statistical analysis was performed by Kruskal–Wallis with Dunnett’s test. Differences were considered significant when p < 0.05.

2.2. In Vivo Experiments. C6 glioma cells (ECACC/Sigma-Aldrich, UK) were grown in a 10 cm Petri dish in 10 ml of high-glucose Dulbecco’s modified eagle medium (DMEM, Sigma-Aldrich, UK) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C in the presence of 5% CO2. Upon reaching approximately 80%
confluence, the cells were washed twice with PBS and trypsinised with 1 ml of 0.4% trypsin solution.

All animal experiments were approved by the Animal Health Welfare and Ethics Committee of University of Eastern Finland. Female Wistar rats (n = 11, 190–380 g, Envigo, UK) were anesthetized with intraperitoneal (i.p.) injection of ketamine 60 mg/kg (Ketalar vet 50 mg/ml, Pfizer, US) and medetomidine hydrochloride 0.4 mg/kg (Domitor vet 1 mg/ml, Orion Pharma Animal Health, Finland). C6 cells (1 × 10^6 C6 cells per 10 μl of ice-cold PBS) were implanted to stereotactic coordinates of 1 mm caudal from bregma, 2 mm to the right of the sagittal suture, and 2 mm below the top of bregma through a burr hole. Animals received postoperation pain medication (Norocarp, Vet Medic Pharmaceuticals Oy, Finland) after surgery.

MRI experiments were performed using a 9.4 T horizontal magnet interfaced to Agilent (Santa Clara, US) imaging console and a volume coil transmitter/4-channel surface coil receiver pair (Rapid Biomedical, Rimpar, Germany) on days 7–14 postsurgery. During the experiments, the animals were anesthetized with isoflurane (5% induction, 1-2% upkeep, 70:30 N₂:O₂ gas mixture at 2 L/min) and placed inside a holder with breath monitoring (60–80 breaths per minute) and temperature control (37°C) using warm water. Axial multislice MRI data covering the tumor and normal brain were first collected. T₁ (inversion-recovery FLASH (Fast Low Angle SHot), 12 inversion times between 5 and 5500 ms, 10 s delay between inversions, TR within FLASH 7.8 ms, TE 3.9 ms, 10° flip angle, 32 × 32 mm² FOV, 128 × 64 data matrix, and twelve 1 mm slices) and T₂ (multi spin-echo with 16 echoes collected between 8.1 and 129.8 ms, TR 2 s, 32 × 32 mm² FOV, 128 × 64 data matrix, and eight 1 mm slices) maps were collected before CA injection and for up to one hour after injection. Fast gradient echo multislice imaging (TR 156 ms, TE 4.5 ms, flip angle 90°, 32 × 32 mm² FOV, 256 × 128 data matrix, and eight 1 mm slices) was performed during CA injection; imaging started 1 min before the start of the injection and continued for 10 mins after the injection. For TEEPO-Glc, the final concentration was 0.5 to 2.2 mmol/kg (injection volume was 6 ml/kg with sample concentration varying between 75 and 277 mM) (n = 7). For Gd(DTPA) (gadopentetate dimeglumine), final concentration was 0.1 mmol/kg (injection volume 1 ml/kg with 100 mM sample concentration; n = 4; one of the animals had received injection of TEEPO-Glc approximately 70 minutes before Gd(DTPA) injection. Additionally, 4-hydroxy-TEMPO (2,2,6,6-tetramethylpiperidin-1-oxyl) at concentration 1.6 mmol/kg was injected (injection volume ∼6 ml/kg, concentration 290 mM; n = 2; one of the animals received a Gd(DTPA) injection 60 minutes later). All data were analyzed in Matlab (Mathworks, Natick, US). Parameter maps were calculated using monoeXponential fits.

3. Results and Discussion

3.1. Toxicity Effects of TEEPO-Glc in HeLa Cells and HUVECs.

To study the in vitro cytotoxicity of TEEPO-Glc, a set of cell viability and LDH release tests were performed in HeLa cells [35] and primary human endothelial cells, HUVECs. Different concentrations of TEEPO-Glc (0.2, 1, and 10 mM) were incubated for 1, 6, and 24 h. The cytotoxicity was studied using cell viability assay (Figures 2(a) and 2(b)) and LDH (lactate dehydrogenase) release assay (Figures 2(c) and 2(d)). The cell viability assay is based on quantitation of ATP (adenosine triphosphate), the amount of ATP being directly proportional to the number of living cells. The LDH release assay is a colorimetric assay for the measurement of cytoplasmic LDH enzyme activity present in all cells. LDH is released rapidly from the cytosol into culture medium upon the damage of plasma membranes of the cells.

As our earlier results showed, at a high concentration of TEEPO-Glc (10 mM) and with long incubation time (24 h), the cellular viability (p < 0.05) of HeLa cells decreased significantly compared with unexposed controls (Figure 2(a)). With lower concentrations (0.2 mM and 1 mM) or shorter incubation times (1 h and 6 h) TEEPO-Glc showed no effect on the cell viability. For HUVECs, TEEPO-Glc caused a significant reduction in cellular viability at a concentration of 10 mM at all detected time points, 1 h, 6 h, and 24 h (p < 0.05) (Figure 2(b)). However, lower concentrations of TEEPO-Glc (0.2 mM or 1 mM) did not have an effect on the cell viability. Concomitantly, results from LDH assay showed that none of the TEEPO-Glc treatments (0.2, 1, or 10 mM) caused significant membrane damage for the cultured HeLa cells (Figure 2(c)), albeit there is a slight increase with the highest concentration (10 mM) with 24 h incubation time. With HUVECs, the 10 mM concentration induced a significant LDH release (p < 0.05) and loss of plasma membrane integrity at all tested time points (1, 6, and 24 h) compared with untreated control cells (Figure 2(d)). Lower concentrations of TEEPO-Glc did not show any membrane-damaging effects for HUVECs at any time points tested. All in all, the TEEPO-Glc contrast agent showed toxicity only at a high 10 mM concentration and can be considered scarcely toxic in concentrations relevant to practical use.

3.2. Relaxation Enhancement Studies with In Vivo MRI.

The relaxation-enhancing properties of TEEPO-Glc were assessed with an in vivo MRI study. In the study, T₁ maps were collected before, during, and after contrast agent injection with an inversion-recovery FLASH imaging sequence. The maps were recorded using both TEEPO-Glc and Gd(DTPA) (gadopentetate dimeglumine) as contrast agents in order to compare the results of TEEPO-Glc to a common GBCA. Figure 3 presents the T₁ values of a representative animal. Figure 3(a) displays the T₁ images of the rat brain at approximately 10 minute intervals starting from the injection of contrast agent and T₁ times with respect to the time after the injection. After 60 minutes of the TEEPO-Glc injection, the animal received the Gd(DTPA) injection. The T₁ values were determined both in tumor and in normal, healthy brain. Their regions of interest (ROI) are outlined in red and blue, respectively, in Figure 3(a). Figure 3(b) displays the average T₁ relaxation times within ROI with respect to the time, and the error bands represent the standard deviation (±SD) within ROI. The differences in the preinjection
$T_1$ times between tumor and normal brain area arise from the existing contrast between healthy and malignant tissue. The results display a clear drop in the $T_1$ relaxation time in tumor after the TEEPO-Glc injection. The effect was at its strongest between 10 and 15 minutes after the injection resulting in a decrease of approximately 20% in $T_1$. After 50 minutes, the $T_1$ value had returned back to the level of preinjection $T_1$ relaxation time. Judging from the high stability of TEEPO-Glc, this is most likely due to the contrast agent clearance instead of bioreduction [35]. In the healthy brain, no decrease in the $T_1$ times was detected. Regarding the accumulation and retention time, TEEPO-Glc showed similar behaviour to Gd(DTPA) in the experiments, albeit the relaxation effect is much higher with Gd(DTPA) (Figure 3). The compared $T_1$ decreases in tumor are also in accordance with the $r_1$ relaxivity values determined for the compounds in vitro. The $r_1$ of TEEPO-Glc was determined to be 0.13 mM$^{-1}$s$^{-1}$ in 9.4 T which is similar to the values calculated from earlier in vitro NMR and phantom MRI studies (0.12 mM$^{-1}$s$^{-1}$ in 11.7 T and 0.23 mM$^{-1}$s$^{-1}$ in 1.5 T field) [35]. The $r_1$ value of Gd(DTPA) is significantly higher, 4 mM$^{-1}$s$^{-1}$ [38], which can be observed as a stronger decrease in the $T_1$ time after the Gd(DTPA) injection. The higher relaxivity of Gd(DTPA) is supposedly due to the fact that gadolinium has seven unpaired electrons, whereas TEEPO-Glc has one unpaired electron. Additionally, with Gd(DTPA), the relaxation enhancement is the result of both inner- and outer-sphere relaxation. Inner-sphere relaxation

Figure 2: TEEPO-Glc cytotoxicity in vitro. Cell viability study with (a) HeLa cells (reproduced from Ref. 35 with permission from The Royal Society of Chemistry) and (b) HUVECs were determined by CellTiter-Glo® assay kit (ATP measurement), and the results (mean ± SD, n = 4) were compared with untreated control cells whose viability was set at 100%. LDH release study with (c) HeLa cells and (d) HUVECs. Control cells were lysed with LDH assay lysis solution and set at 100% (lysis). The level of significance was set at a probability of $p < 0.05$ (*) when compared with untreated control cells (Kruskal–Wallis with Dunnett’s test).
is caused by the water molecule directly coordinating to the paramagnetic center, and outer-sphere relaxation is a result of water molecules diffusing close to the contrast agent molecule [1, 2]. With TEEPO-Glc, only the outer-sphere relaxation is relevant as there is no direct bond between the water molecule and the nitroxide. The \( T_2 \) values in tumor were not affected by TEEPO-Glc even though it showed a good contrast in the previous phantom study. Similar to GBCAs, nitroxides seem to shorten both \( T_1 \) and \( T_2 \) times, but the relative effect in tissue is much smaller for \( T_2 \) than for \( T_1 \) making them primarily \( T_1 \) contrast agents [1].

Concentration of TEEPO-Glc was varied across the experiments to assess the effect of dose on the apparent CA concentration in the tumor. The relative concentrations were calculated from the relaxation rates \( (R_1 = 1/T_1) \) and the \( r_1 \) values \((0.13 \text{ mM}^{-1} \text{s}^{-1} \text{ for TEEPO-Glc and } 4 \text{ mM}^{-1} \text{s}^{-1} \text{ for Gd(DTPA)})\). The apparent maximal tumor concentrations measured at \( \sim 10 \text{ mins} \) after injection for both compounds are shown in Table 1. Although lower apparent concentration was observed at the lowest injected dose \( (0.5 \text{ mmol/kg}) \), the higher TEEPO-Glc doses all showed relatively similar apparent tumor concentrations. The concentrations have also been normalized to the injected dose \( (\mu \text{ mol}) \) to derive an approximate %ID/g value (percent of injected dose per gram of tissue) (Table 1). The apparent %ID/g were \( 0.19 \pm 0.09 \) and \( 0.25 \pm 0.09 \), for TEEPO-Glc and Gd(DTPA), respectively. This implies similar initial uptake of the two contrast agents despite different concentrations. The underlined animal (animal 3) received both TEEPO-Glc and Gd(DTPA) injection (see Table 1).

The apparent contrast agent concentrations in the tumor ROI are presented with respect to postinjection time in Figure 4. The %ID/g is presented as an average of all the animals listed in Table 1. The loss of TEEPO-Glc contrast was faster than Gd(DTPA) \( (p < 0.01, \text{ Student’s } t\text{-test, Figure 4}) \), with a mean lifetime of \( 23 \pm 8 \text{ min} \) and \( 49 \pm 10 \text{ min} \) for TEEPO-Glc and Gd(DTPA), respectively. Together the
results on apparent TEEPO-Glc concentration in tumor and the fast elimination indicate low targeting effect. Consequently, we were interested in looking into the accumulation and relaxation enhancing properties of the radical moiety without the glucose unit. However, the nitroxide radical, 4-hydroxy-TEEPO, is highly lipophilic and consequently insoluble in either pure saline or saline doped with 10% DMSO or TWEEN20/80 at desired concentrations and could not act as a reference to review the targeting effect of the glucose unit. Additionally, 4-hydroxy-TEMPO (2,2,6,6-tetramethylpiperidin-1-oxyl) was soluble in saline doped with DMSO but did not show any change in $T_1$ relaxation times at 10 minutes, suggesting it underwent rapid bioreduction and lost its paramagnetism ruling it out as a reference.

### 4. Conclusions

As a conclusion, we have developed a fully organic, stable, and water-soluble compound with the ability to enhance relaxation in MRI. The compound displayed similar behavior to an existing MRI contrast agent, Gd(DTPA), concerning accumulation and retention in the tumor area. Unfortunately, the targeting effects could not be confirmed with this study. Also, due to the low relaxivity of the compound, it is an unlikely candidate to replace the existing contrast agents as such. However, this compound could be expected to bring an addition to the established MRI diagnostics by opening new ways to study the growing group of metal-free contrast agents for MRI.

### Table 1: Apparent tumor CA concentration in each animal.

| Animal | Injected dose (μmol/g) | Injected dose (μmol) | Apparent tumor concentration (mM~μmol/g) | %ID/g |
|--------|------------------------|----------------------|----------------------------------------|-------|
| TEEPO-Glc |                        |                      |                                        |       |
| 1      | 2.2                    | 693                  | 0.67                                   | 0.10  |
| 2      | 1.6                    | 615                  | 0.85                                   | 0.14  |
| 3      | 1.2                    | 385                  | 0.83                                   | 0.22  |
| 4      | 1.2                    | 285                  | 0.59                                   | 0.21  |
| 5      | 1.0                    | 206                  | 0.65                                   | 0.32  |
| 6      | 1.0                    | 210                  | 0.48                                   | 0.23  |
| 7      | 0.5                    | 105                  | 0.09                                   | 0.09  |
| Average | 0.19 ± 0.08            |                      |                                        |       |
| Gd(DTPA) |                       |                      |                                        |       |
| 3      | 0.1                    | 34                   | 0.12                                   | 0.37  |
| 8      | 0.1                    | 37                   | 0.05                                   | 0.15  |
| 9      | 0.1                    | 37                   | 0.09                                   | 0.24  |
| 10     | 0.1                    | 33                   | 0.09                                   | 0.27  |
| Average | 0.25 ± 0.09            |                      |                                        |       |

**Figure 4:** Apparent CA concentrations of TEEPO-Glc and Gd(DTPA) as a function of time postinjection. TEEPO-Glc was disappearing from tumor at a faster rate than Gd-DTPA.
Data Availability

The graphical data used to support the findings of this study are included within the article. The numerical data used to form the graphs are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

MS would like to acknowledge the Finnish Cultural Foundation for financial support. In vivo and in vitro experiments were partially funded by the Academy of Finland (project grants no. 286895 and 314412) and TEKES/EU Regional Development Fund (no. 4298/31/2014). The authors thank Ms. Maarit Pulkinnen, Ms. Viivi Hyppönen, and Ms. Anne Martikainen for their excellent technical assistance during the project.

References

[1] P. Caravan, J. J. Ellison, T. J. McMurry, and R. B. Lauffer, “Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications,” Chemical Reviews, vol. 99, no. 9, pp. 2293–2352, 1999.

[2] L. M. De León-Rodríguez, A. F. Martins, M. C. Pinho, N. M. Rofsky, and A. D. Sherry, “Basic MR relaxation mechanisms and contrast agent design,” Journal of Magnetic Resonance Imaging, vol. 42, no. 3, pp. 545–565, 2015.

[3] A. D. Sherry, P. Caravan, and R. E. Lenkinski, “Primer on gadolinium chemistry,” Journal of Magnetic Resonance Imaging, vol. 30, no. 6, pp. 1240–1248, 2009.

[4] T. Kanda, T. Fukusato, M. Matsuda et al., “Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectrometry,” Radiology, vol. 276, no. 1, pp. 228–232, 2015.

[5] J. Rogowska, E. Olkowska, W. Ratajczyk, and L. Wolska, “Gadolinium as a new emerging contaminant of aquatic environments,” Environmental Toxicology and Chemistry, vol. 37, no. 6, pp. 1523–1534, 2018.

[6] S. Kulakisz and M. Bau, “Anthropogenic gadolinium as a microcontaminant in tap water used as drinking water in urban areas and megacities,” Applied Geochemistry, vol. 26, no. 11, pp. 1877–1885, 2011.

[7] K. W. Y. Chan, J. W. M. Bulte, and M. T. McMahon, “Diamagnetic chemical exchange saturation transfer (diaC-EST) liposomes: physicochemical properties and imaging applications,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, vol. 6, no. 1, pp. 111–124, 2014.

[8] G. Liu, X. Song, K. W. Y. Chan, and M. T. McMahon, “Nuts and bolts of chemical exchange saturation transfer MRI,” NMR in Biomedicine, vol. 26, no. 7, pp. 810–828, 2013.

[9] A. Gamliel, S. Uppala, G. Sapir et al., “Hyperpolarized [13N] nitrate as a potential long lived hyperpolarized contrast agent for MRI,” Journal of Magnetic Resonance, vol. 299, pp. 188–195, 2019.

[10] E. B. Adamson, K. D. Ludwig, D. G. Mummy, and S. B. Fain, “Magnetic resonance imaging with hyperpolarized agents: methods and applications,” Physics in Medicine and Biology, vol. 62, no. 13, pp. R81–R123, 2017.

[11] R. Brasch, D. Nitecki, M. Brant-Zawadzki et al., “Brain nuclear magnetic resonance imaging enhanced by a paramagnetic nitroxide contrast agent: preliminary report,” American Journal of Roentgenology, vol. 141, no. 5, pp. 1019–1023, 1983.

[12] L. T. Paletta, M. Pink, B. Foley, S. Rajca, and A. Rajca, “Nitroxides: applications in synthesis and in polymer chemistry,” Angewandte Chemie International Edition, vol. 50, no. 22, pp. 5044–5068, 2011.

[13] E. I. Izgorodina, “Toward improved performance of all-or-none nitroxide radical batteries with ionic liquids: a theoretical perspective,” ACS Sustainable Chemistry & Engineering, vol. 7, no. 5, pp. 5367–5375, 2019.

[14] E. B. Adamson, K. D. Ludwig, D. G. Mummy, and S. B. Fain, “Magnetic resonance imaging with hyperpolarized agents: methods and applications,” Physics in Medicine and Biology, vol. 62, no. 13, pp. R81–R123, 2017.

[15] R. Brasch, D. Nitecki, M. Brant-Zawadzki et al., “Brain nuclear magnetic resonance imaging enhanced by a paramagnetic nitroxide contrast agent: preliminary report,” American Journal of Roentgenology, vol. 141, no. 5, pp. 1019–1023, 1983.

[16] L. Wylie, K. Oyaizu, A. Karton, M. Yoshizawa-Fujita, and B. Charleux, “Nitroxide-mediated polymerization,” Progress in Polymer Science, vol. 38, no. 1, pp. 63–235, 2013.

[17] M. M. Haugland, J. E. Lovett, and E. A. Anderson, “Advances in the synthesis of nitroxide radicals for use in biomolecule spin labelling,” Chemical Society Reviews, vol. 47, no. 3, pp. 668–680, 2018.

[18] J. Nicolas, Y. Guillauneuf, C. Lefay, D. Bertin, D. Gignes, and B. Charleux, “Nitroxide-mediated polymerization,” Progress in Polymer Science, vol. 38, no. 1, pp. 63–235, 2013.

[19] E. B. Adamson, K. D. Ludwig, D. G. Mummy, and S. B. Fain, “Magnetic resonance imaging with hyperpolarized agents: methods and applications,” Physics in Medicine and Biology, vol. 62, no. 13, pp. R81–R123, 2017.

[20] R. Brasch, D. Nitecki, M. Brant-Zawadzki et al., “Brain nuclear magnetic resonance imaging enhanced by a paramagnetic nitroxide contrast agent: preliminary report,” American Journal of Roentgenology, vol. 141, no. 5, pp. 1019–1023, 1983.

[21] E. B. Adamson, K. D. Ludwig, D. G. Mummy, and S. B. Fain, “Magnetic resonance imaging with hyperpolarized agents: methods and applications,” Physics in Medicine and Biology, vol. 62, no. 13, pp. R81–R123, 2017.

[22] R. Brasch, D. Nitecki, M. Brant-Zawadzki et al., “Brain nuclear magnetic resonance imaging enhanced by a paramagnetic nitroxide contrast agent: preliminary report,” American Journal of Roentgenology, vol. 141, no. 5, pp. 1019–1023, 1983.

[23] E. B. Adamson, K. D. Ludwig, D. G. Mummy, and S. B. Fain, “Magnetic resonance imaging with hyperpolarized agents: methods and applications,” Physics in Medicine and Biology, vol. 62, no. 13, pp. R81–R123, 2017.

[24] R. Brasch, D. Nitecki, M. Brant-Zawadzki et al., “Brain nuclear magnetic resonance imaging enhanced by a paramagnetic nitroxide contrast agent: preliminary report,” American Journal of Roentgenology, vol. 141, no. 5, pp. 1019–1023, 1983.

[25] E. B. Adamson, K. D. Ludwig, D. G. Mummy, and S. B. Fain, “Magnetic resonance imaging with hyperpolarized agents: methods and applications,” Physics in Medicine and Biology, vol. 62, no. 13, pp. R81–R123, 2017.

[26] R. Brasch, D. Nitecki, M. Brant-Zawadzki et al., “Brain nuclear magnetic resonance imaging enhanced by a paramagnetic nitroxide contrast agent: preliminary report,” American Journal of Roentgenology, vol. 141, no. 5, pp. 1019–1023, 1983.
hydration or dehydration processes,” *Langmuir*, vol. 33, no. 31, pp. 7810–7817, 2017.

[27] J. M. W. Chan, R. J. Wojtecki, H. Sardon et al., “Self-assembled, biodegradable magnetic resonance imaging agents: organic radical-functionalized diblock copolymers,” *ACS Macro Letters*, vol. 6, no. 2, pp. 176–180, 2017.

[28] K. Morishita, S. Ueki, Y. Fuchi et al., “Self-assembled biradical urea benzene nanoparticles for magnetic resonance imaging,” *ACS Applied Nano Materials*, vol. 1, no. 12, pp. 6967–6975, 2018.

[29] M. Dharmarwardana, A. F. Martins, Z. Chen et al., “Nitroxyl modified tobacco mosaic virus as a metal-free high-relaxivity MRI and EPR active superoxide sensor,” *Molecular Pharmaceutics*, vol. 15, no. 8, pp. 2973–2983, 2018.

[30] H. V.-T. Nguyen, A. Detappe, N. M. Gallagher et al., “Triply loaded nitroxide brush-arm star polymers enable metal-free millimetric tumor detection by magnetic resonance imaging,” *ACS Nano*, vol. 12, no. 11, pp. 11343–11354, 2018.

[31] G. G. Alvaredo, H. V.-T. Nguyen, P. Harvey et al., “Poly-oxazoline-based bottlebrush and brush-arm star polymers via ROMP: syntheses and applications as organic radical contrast agents,” *ACS Macro Letters*, vol. 8, no. 4, pp. 473–478, 2019.

[32] Z. Zhelev, R. Bakalova, I. Aoki et al., “Nitroxyl radicals for labeling of conventional therapeutics and noninvasive magnetic resonance imaging of their permeability for blood–brain barrier: relationship between structure, blood clearance, and MRI signal dynamic in the brain,” *Molecular Pharmaceutics*, vol. 6, no. 2, pp. 504–512, 2009.

[33] M. C. Emoto, K.-i. Yamada, M. Yamato, and H. G. Fujii, “Novel ascorbic acid-resistant nitroxide in a lipid emulsion: an efficient brain imaging contrast agent for MRI of small rodents,” *Neuroscience Letters*, vol. 546, pp. 11–15, 2013.

[34] M. C. Emoto, S. Sato, and H. G. Fujii, “Development of nitroxide-based theranostic compounds that act both as anti-inflammatory drugs and brain redox imaging probes in MRI,” *Magnetic Resonance in Chemistry*, vol. 54, no. 9, pp. 705–711, 2016.

[35] M. Soikkeli, K. Sievänen, J. Peltonen et al., “Synthesis and in vitro phantom NMR and MRI studies of fully organic free radicals, TEEPO-glucose and TEMPO-glucose, potential contrast agents for MRI,” *RSC Advances*, vol. 5, no. 20, pp. 15507–15510, 2015.

[36] M. Soikkeli, K. Horkka, J. O. Moilanen, M. Timonen, J. Kavakka, and S. Heikkinen, “Synthesis, stability and relaxivity of TEEPO-met: an organic radical as a potential tumour targeting contrast agent for magnetic resonance imaging,” *Molecules*, vol. 23, no. 5, p. 1034, 2018.

[37] S. Vallabhajosula, “18F-Labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization,” *Seminars in Nuclear Medicine*, vol. 37, no. 6, pp. 400–419, 2007.

[38] M. Rohrer, H. Bauer, J. Mintorovitch, M. Requardt, and H.-J. Weinmann, “Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths,” *Investigative Radiology*, vol. 40, no. 11, pp. 715–724, 2005.